Resolutions from the Annual General Meeting of Novo Nordisk A/S
March 21, 2024 10:59 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 21 March 2024 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors communicated: “We are very...
Novo Nordisk A/S - share repurchase programme
March 18, 2024 10:18 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 18 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Global Antidiabetics Market Report 2024 - A $313.9 Billion Market by 2034, with CAGR of 10.9% During 2024-2034
March 18, 2024 05:10 ET
|
Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Global Antidiabetics Market by Product Type, by Application, by Distribution channel, and By Region" report has been added to ...
Novo Nordisk A/S - share repurchase programme
March 11, 2024 08:46 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 11 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Non-Alcoholic Steatohepatitis Treatment Market revenue to reach USD 48.3 Billion by 2035, says Research Nester
March 06, 2024 06:00 ET
|
Research Nester
New York , March 06, 2024 (GLOBE NEWSWIRE) -- The global non-alcoholic steatohepatitis treatment market size is predicted to expand at 18% CAGR between 2023 and 2035. The market is projected to...
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
March 05, 2024 04:53 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to...
Novo Nordisk A/S - share repurchase programme
March 04, 2024 09:29 ET
|
Novo Nordisk A/S
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 04 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No...
Global Insulin Market Size to Surpass USD 41.63 Billion by 2033
February 27, 2024 11:00 ET
|
Precedence Research
Ottawa, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The global insulin market size stood at USD 28.64 billion in 2024, grew to USD 29.10 billion in 2025, and is anticipated to reach around USD 38.95 billion...
Novo Nordisk A/S - share repurchase programme
February 26, 2024 06:02 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 26 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Notice for the Annual General Meeting of Novo Nordisk A/S
February 21, 2024 09:03 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 21 February 2024 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 21 March 2024 at 14.00 (CET) The Annual General Meeting is held as a partially...